a b s t r a c t PHT1 (SLC15A4) is responsible for translocating L-histidine (L-His), di/tripeptides and peptide-like drugs across biological membranes. Previous studies have indicated that PHT1 is located in brain parenchyma, however, its role and significance in brain along with effect on the biodistribution of substrates is unknown. In this study, adult gender-matched Pht1-competent (wildtype) and Pht1-deficient (null) mice were used to investigate the effect of PHT1 on L-His brain disposition via in vitro slice and in vivo pharmacokinetic approaches. We also evaluated the serum clinical chemistry and expression levels of select transporters and enzymes in the two genotypes. No significant differences were observed between genotypes in serum chemistry, body weight, viability and fertility. PCR analyses indicated that Pept2 had a compensatory up-regulation in Pht1 null mice (about 2-fold) as compared to wildtype animals, which was consistent in different brain regions and confirmed by immunoblots. The uptake of L-His was reduced in brain slices by 50% during PHT1 ablation. The L-amino acid transporters accounted for 30% of the uptake, and passive (other) pathways for 20% of the uptake. During the in vivo pharmacokinetic studies, plasma concentration-time profiles of L-His were comparable between the two genotypes after intravenous administration. Still, biodistribution studies revealed that, when sampled 5 min after dosing, L-His values were 28-48% lower in Pht1 null mice, as compared to wildtype animals, in brain parenchyma but not cerebrospinal fluid. These findings suggest that PHT1 may play an important role in histidine transport in brain, and resultant effects on histidine/histamine homeostasis and neuropeptide regulation.
Introduction
PHT1 (SLC15A4), a member of the proton-coupled oligopeptide transporter (POT) superfamily, is responsible for translocating various di/tripeptides and peptide-like drugs across biological membranes, as well as the amino acid L-histidine [1] . Unlike two other peptide transporters, PEPT1 (SLC15A1) and PEPT2 (SLC15A2), which have been well studied, there is little known about PHT1 expression, localization, function and pharmacological relevance. PHT1 is abundantly found in the brain and eye [2, 3] . PHT1 has an age-dependent increase in brain expression [4] , similar to the changes found in the histaminergic system [5] [6] [7] [8] [9] . In contrast, PEPT2 shows an age-dependent decrease in brain expression and PHT1 function dominated in the uptake of a dipeptide in brain slices from adult rodents, suggesting a significant role in regulating both endogenous and exogenous L-histidine (L-His) and peptides/ mimetics in brain [4] . PHT1 transcripts are also detected in rat thyroid gland [10] and skeletal muscle [11] . A recent study showed that PHT1 and PHT2 are involved in the immune response [12] . These authors reported that PHTs were preferentially expressed in dendritic cells, located at endosomes and lysosomes, mediating the release of bacterially derived components into the cytosol.
L-Histidine (L-His) is one of the proteinogenic amino acids, which is obtained from dietary metabolism and protein turnover [13] . L-His possesses several crucial biological functions, including formation of the myelin sheath, detoxification of heavy metals, and the manufacturing of white and red blood cells. It is also a precursor of histamine, carnosine, ergothioneine, and vitamin C [14] . Studies on the transport of L-His in brain would extend our understanding of neuropeptide regulation, histamine homeostasis, and potential targets for drug delivery to neuronal and non-neuronal cells. In the central nervous system (CNS), major transporters for L-His include the Na (e.g., SNATs, which belong to the SLC38 family) [15, 16] , Na + -independent amino acid transporters (e.g., LATs and CATs, which belong to the SLC7 family) [17, 18] , some members of the Na + -and Cl À -dependent neurotransmitter transporter family (e.g., B 0 AT2 and NTT4, which belong to the SLC6 family) [19] [20] [21] , as well as the peptide/histidine transporters (e.g., PHT1 and PHT2, which belong to the SLC15 family) [4, 22] .
Histamine, one of the most important metabolites of L-His, is formed in the brain during catalysis by histidine decarboxylase (HDC). While much of the research effort has focused on the enzymatic production of histamine via HDC, little attention has been paid to the mechanism by which L-His gains entry into neurons. Due to its polarity and lack of a transport system, histamine cannot pass through the barrier systems of the brain [23] . Moreover, the availability of its precursor, L-His, is positively correlated with brain histamine production and, consequently the regulatory functions of histamine [24, 25] . Significant changes in brain histamine levels have been observed in several neurological diseases, such as multiple sclerosis, Alzheimer's disease, Down's syndrome and Wernicke's encephalopathy [26] . Dysfunction of HDC and the LHis transporters in brain may be related to these neurological disorders.
In the present study, we hypothesized that PHT1 ablation would substantially reduce the uptake of L-His in the brain of adult mice. Initial phenotypic analyses were performed in Pht1-competent (wildtype) and Pht1-deficient (null) mice, along with gene expression levels of POTs and select transporter/enzyme proteins. Subsequent studies evaluated the functional activity of PHT1 by studying the in vitro uptake of L-His in regional brain slices, and the in vivo pharmacokinetics and biodistribution of L-His after intravenous administration. ]dextran-70,000 (110 mCi/mg) were purchased from American Radiolabeled Chemicals (St. Louis, MO). Unlabeled L-histidine, mannitol and dextran-70,000 were purchased from Sigma-Aldrich (St. Louis, MO). Protease inhibitor cocktail was purchased from Roche (Seattle, WA). Power SYBR Green PCR Master Mix was purchased from Applied Biosystems (Foster City, CA). All other chemicals were obtained from standard sources.
Materials and methods

Chemicals
Animals
Gender-and age-matched Pht1-competent (wildtype or Pht1 +/+ ) and Pht1-deficient (null or Pht1 À/À ) mice, 7-10 week old, were used in this study [27] . PCR analysis, using genomic DNA isolated from tail biopsies, was performed to confirm the subsequent production of Pht1 null mice. The Pht1 gene had a forward primer 5 0 -GATCGAGGTCCAGAAGCCACTCG-3 0 and a reverse primer 5 0 -GAGT TGTGTCACTCACCCACTTCT-3 0 . The Neo gene, inserted during homologous recombination in Pht1 null mice, had a forward primer 5 0 -GGAGAGGCTATTCGGCTATG-3 0 and a reverse primer 5 0 -GCTCTT CAGCAATATCACGG-3 0 . All animals were bred on a C57BL/6 background (P99%). The mice were housed in a temperaturecontrolled environment with 12 h light and dark cycles, and received a standard diet and water ad libitum (Unit of Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI). All mouse studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
Initial phenotypic analyses
Pht1 null mice were evaluated for body weight and serum clinical chemistry in comparison to those of wildtype mice (by Animal Diagnostic Core, ULAM, University of Michigan, Ann Arbor, MI), as described previously for Pept1 null mice [28] . Viability and fertility were also monitored.
Gene and protein expression
Quantitation of POTs (Pept1, Pept2, Pht1 and Pht2), select amino acid transporters (Lat1, Snat1, Snat3 and Ntt4) and histidine decarboxylase (Hdc) was performed in several tissues of adult wildtype and Pht1 null mice using a 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA) [29] . Tissues of interest included cerebral cortex, cerebellum, hippocampus, hypothalamus and choroid plexus. In brief, 2.0 lg of total RNA, isolated using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), was reverse-transcribed into cDNA using the Omniscript RT Kit (Qiagen, Valencia, CA) with 16-mer random primers. The mouse Gapdh gene was used as an internal control of cDNA quality and quantity. The primers were designed using Primer 3.0 (Applied Biosystems, Foster City, CA) and synthesized by Integrated DNA Technologies (Coraville, IA) ( Table 1 ). The real-time PCR thermal conditions were 1 cycle at 50°C for 2 min, 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 s and then 60°C for 1 min. The DCT method was used to calculate the relative levels of target gene transcripts in mice, where the ratio of target gene to Gapdh was equal to 2 ÀDCT , DCT = CT(gene) À CT(Gapdh). Immunoblot analysis was performed for PEPT2 protein, as described previously with minor changes [30] . Tissue lysis buffer consisted of neuronal protein extraction reagent (Thermo Scientific, Rockford, IL) with the addition of proteinase inhibitor cocktail. Kidney protein served as positive control for PEPT2 [31] .
In vitro uptake of L-His in regional brain slices
Adult wildtype and Pht1 null mice were used to evaluate the contribution of PHT1 in L-His uptake. Brain slices, prepared using a method described previously [4] , were incubated in buffer con- 4 ). Incubation times were 1, 3, 5 and 10 min, after which time 1.5 mL ice-cold aCSF buffer was added to the chamber to terminate the reaction. The samples were immediately filtered through 100 lm nylon mesh and then washed five times with 1.5 mL ice-cold aCSF buffer. The filter (and tissue slices) were transferred to a scintillation vial containing 0.33 mL hyamine hydroxide and left overnight at 37°C to dissolve the tissue. The samples were then mixed with a 7.0-mL aliquot of Cytoscint cocktail (MP Biomedicals, Solon, OH). Radioactivity was measured using a Beckman LS 6000 SC dual-channel liquid scintillation counter (Beckman Coulter Inc., Fullerton, CA). The uptake of L-His in brain slices was determined using the following equation [32] : where uptake was calculated as lL/mg wet tissue weight. The subscript t represents the total radioactivity, f the filter-binding and media the concentration of drug in the incubation media.
To further investigate the contribution of amino acid transporters on L-His uptake, as well as the substrate specificity of PHT1, excess concentrations (5 mM) of L-His, L-glutamine, Lleucine, L-asparagine or BCH (2-amino-2-norbornanecarboxylic acid) were added as inhibitors of the amino acid transporters. Similarly, dipeptides (glycylsarcosine and carnosine) were used as inhibitors of the peptide transporters. These studies were performed on hypothalamus slices following a 3-min incubation period.
In vivo pharmacokinetics and biodistribution of L-His
L-His solutions were prepared by mixing appropriate amounts of [ A noncompartmental pharmacokinetic analysis of L-His was performed on the plasma concentrations of L-His after intravenous bolus dosing using Phoenix/WinNonlin version 6.4 (Pharsight Inc. Mountain View, CA). Total area under the plasma concentrationtime curve (AUC) was calculated using the trapezoidal rule. Clearance (CL), volume of distribution (V ss ), half-life (t 1/2 ), terminal disposition rate constant (k z ) and mean residence time (MRT) were calculated using standard methods.
Statistics
All the experimental results were reported as mean ± SE. A twotailed unpaired Student t test was applied when comparing statistical differences between two treatment groups. For multiple comparisons, one-way analysis of variance (ANOVA) was used followed by Tukey's test for pairwise comparisons between all the treatment groups. A p value 60.05 was considered significant. All linear and nonlinear regressions were performed by Prism v5.0 (GraphPad Software, Inc., La Jolla, CA).
Results
Identification and initial phenotypic analyses of Pht1 null mice
These studies were performed to test for obvious differences in fundamental characteristics between the two mouse genotypes. In this regard, PCR analyses of genomic DNA extracted from tail biopsies demonstrated that Pht1 genomic DNA was present in wildtype but not Pht1 null mice (Fig. 1) . Since Pht1 null primers were designed specifically to target the Neo gene, a band was observed in Pht1 null mice but not in wildtype animals. No obvious behavioral abnormality was observed in Pht1 null mice when compared with wildtype animals. Pht1 null mice were fertile and appeared healthy. There were no significant differences between genotypes in body weight or in any of the serum clinical chemistry values (Table 2) .
Gene and protein expression
The purpose of these studies was to determine if Pht1 mice were different, as compared to wildtype animals, in their gene expression of POT family members and other relevant transporters and enzymes. Protein expression for a particular transporter was also performed in select cases. PCR analyses in wildtype mice indicated that Pht1 was expressed, along with Pept2, in the cerebral cortex, cerebellum, hypothalamus, hippocampus and choroid plexus (Fig. 2) . Interestingly, Pept2 showed a compensatory Table 1 Quantitative real-time PCR primers in mouse.
Gene
Forward Primer (5
Hdc, histidine decarboxylase. up-regulation in Pht1 null mice (about 2-fold), which was consistently observed in the different brain regions. Expression of other peptide transporters (Pept1 and Pht2) and Hdc were comparable between the two genotypes. Some of the amino acid transporters had different transcription levels between genotypes, however, there was no consistent pattern in the different brain regions. The upregulation of Pept2 in Pht1 null mouse brain was confirmed by immunoblot analysis (Fig. 3) . PEPT2 protein could be detected in different brain regions, in which expression was increased about 2-fold in the cerebral cortex, hippocampus and hypothalamus of Pht1 null mice as compared to wildtype animals.
In vitro uptake of L-His in regional brain slices
These studies were performed to examine if regional functional activity, along with substrate specificity, differed between wildtype and Pht1 null mice in the brain uptake of a model substrate, L-His, using an in vitro model. L-[ 3 H]His uptake was linearly correlated with time over the first 3-10 min, with no consistent trend for either genotype or regional brain slice (Fig. 4A-D) . As a result, 3-min uptakes were used to estimate the initial rates of L-His, which were reduced by 37-60% during PHT1 ablation depending 3.9 ± 0.5 (6) 4.5 ± 0.9 (6) Protein (g/dL)
8.2 ± 1.9 (6) 6.7 ± 1.5 ( upon the regional brain slice studied (Fig. 4E) . To assess the substrate specificity of PHT1, the 3-min uptake of L-[ 3 H]His was evaluated in hypothalamus by inhibition studies (Fig. 5) . In wildtype mice, the uptake of L-His was reduced to 20% of normal by the amino acids L-histidine, L-glutamine, L-lysine and L-asparagine, and to 45-72% of normal by the dipeptides glycylsarcosine and carnosine (5 mM each). In contrast, residual uptake values of L-His in Pht1 null mice were similar between control animals (L-His alone) and in the presence of dipeptides. In the presence of amino acids, values for L-His uptake were significantly reduced in Pht1 null mice, and similar between the two genotypes. Finally, in comparing control values, the uptake of L-His in Pht1 null mice was 50% of that observed in wildtype animals.
In vivo pharmacokinetics and biodistribution of L-His
These studies were designed to evaluate whether or not the in vivo distribution of a model Pht1 substrate, L-His, was different between genotypes with respect to its systemic plasma exposure, accumulation in regional brain sections and CSF concentrations. In this regard, we found that the plasma concentration-time profiles of L- [ 14 C]His after intravenous injection were comparable in wildtype and Pht1 null mice (Fig. 6) . As a result, the pharmacokinetic properties of L-His were not different between the two genotypes, as judged by noncompartmental analyses (Table 3) . Still, biodistribution studies in brain revealed that L-His values were 28-48% lower in Pht1 null mice, as compared to wildtype animals, in the cerebral cortex, cerebellum, hippocampus and hypothalamus, but not CSF, when sampled 5 min after dosing (Fig. 7) .
Discussion
Compared with PEPT1 and PEPT2, little is known about the expression, localization, function and pharmacological relevance of PHT1, another member of the SLC15 family. Based on limited previous reports [2, 4] , PHT1 protein was expressed in the brain and retina of rat, and showed high affinity for L-His in Pht1-transfected Xenopus laevis oocytes [2] . PHT1 protein was also expressed in the brain of adult but not neonatal rats and mice, showing a dominant role in glycylsarcosine brain uptake in adult rodents [4] . However, the significance of PHT1 in uptake of its amino acid substrate, L-His, in brain was not evaluated in these studies [4] . Thus, the in vitro brain slice and in vivo pharmacokinetic/biodistribution studies proposed here for L-His in brain are a good starting point from which to understand the role and significance of PHT1 in neuropeptide regulation, histamine homeostasis, and the potential for targeted drug delivery to neuronal and non-neuronal cell types.
Several novel findings were revealed through phenotypic analyses, in vitro brain slice uptake incubation and in vivo pharmacoki- netic studies in wildtype and Pht1 null mice. Specifically: 1) Pht1 null mice displayed no obvious phenotype and had serum clinical chemistry values that were comparable to wildtype mice; 2) PHT1 was expressed, along with PEPT2, in the brain parenchyma (cortex, cerebellum, hippocampus and hypothalamus) of wildtype mice; 3) the mRNA and protein levels of PEPT2 were significantly up-regulated in Pht1 null mouse brain, suggesting a compensatory role of PEPT2 in these mice; 4) the uptake of L- The results in Fig. 5 indicated there were key differences (and similarities) in the inhibition profiles of wildtype and Pht1 null mice. For example, in comparing the inhibition studies in wildtype mice alone, the amino acids (except for leucine) reduced the uptake of L-His to about 20% of control, whereas the dipeptides reduced L-His uptake to 40-65% of control (all changes were significant). These profiles reflected the collective contributions of PHT1, amino acid transporters and nonsaturable/passive pathways for the uptake of L-His in wildtype mice. In comparing the inhibition studies in Pht1 null mice alone, the same amino acids resulted in significant changes from control, however, L-His uptake in the presence of dipeptides was not significantly different. Most importantly, the control value in Pht1 null mice was only 50% of the control value in wildtype mice, indicating a major influence of PHT1 in the uptake of L-His. Thus, these profiles reflected the collective contributions of amino acid transporters and nonsaturable/passive pathways for the uptake of L-His in the absence of PHT1. Overall, the combined mechanisms for L-His uptake in brain (hypothalamus) were PHT1 (50%), amino acid transporters (30%) and nonsaturable/passive processes (20%).
Of the POTs, PEPT2 is expressed in the brain of adult rats, especially in epithelial cells of the choroid plexus [30] . The brain expression of PEPT2 is maximal in the fetus, declining with age to 14% of those levels in the adult brain. In contrast, the expression and function of PHT1 protein gradually increases with age, agree- Pht1 null (Null) mice after 1 nmol/g intravenous bolus dose. Data are expressed as mean ± SE (n = 11 for WT and 12 for Null) in which the y-axis is displayed on a linear scale (A) and on a logarithmic scale (B). ing with its function as indicated by the uptake of glycylsarcosine in adult rodent brain slices [4] . Another POT, PHT2 can also recognize L-His as a substrate, but this transporter is barely detected in brain [3, 4] , as is PEPT1 [30] . The effect of Pht1 depletion on the transcription of those other POTs, amino acid transporters and related enzymes, as well as on the total brain entry of L-His was unknown and the present study was able to address this with the availability of Pht1 null mice [27, 33] . PEPT2 protein was upregulated in different brain regions of Pht1 null mice, which may suggest a compensatory role of PEPT2 as a transporter for di/ tripeptides in brain (Fig. 3) . This was not observed in other tissues, such as kidney, testis, lung, intestine, spleen or colon (data not shown). As expected, there was no gene expression of Pept1 or Pht2 in the brain of both genotypes, which was consistent with previous studies in wildtype rodents [4] . Interestingly, in rat synaptosomes prepared from cerebral cortex [34] , the uptake of L-His (2 lM) was not inhibited by GlySar (2.5 mM) nor was the uptake of GlySar (20 lM) inhibited by L-His (2.5 mM). Thus, the functional data of Fujita et al. [34] in synaptosomes suggest that, although PHT1 expression will not be synaptic, its expression may reflect a cell body or axonal distribution in neurons. Although brain barrier systems determine the concentration of amino acids in CSF and extracellular fluid (ECF), transporters expressed on the membranes of brain parenchyma cells also participate in the regulation of intracellular fluid homeostasis [35] . More importantly, transporters in brain parenchyma are responsible for the translocation of metabolic substrates, neurotransmitters and neurotransmitter precursors, which can regulate signaling pathways [36] . Amino acid transporters of L-His in brain parenchyma include the Na + -dependent neutral amino acid transporters (SNATs, SLC38 family) [15, 16] , some members of the sodiumand chloride-dependent neurotransmitter transporter family (SLC6 family) (e.g., B 0 AT2, and NTT4) [19] [20] [21] , Na + -independent amino acid transporters (e.g., LATs and CATs, belong to SLC7 family) [17, 18] , and the peptide/histidine transporter PHT1 [4, 22] . Among the amino acid transporters tested in the present study, NTT4, SNAT1 and SNAT3 showed extensive transcription. SNATs have a very broad tissue distribution and are responsible for the net flux of amino acids in CNS [15, 37] . The major physiological function of SNATs in the central nervous system is to transport glutamine in the glutamate/glutamine cycle [38] . Affinity of SNATs to L-His is relatively low, with Michaelis-Menten (K m ) values in the millimolar range [39] [40] [41] . NTT4 (SLC6A17) is identified only in the nervous system, especially in synaptic vesicles [42] , with a Km of 1-2 mM for proline and glycine and interestingly no affinity for L-His [43] . Another important consideration was that of differences in the gene expression of amino acid transporters in wildtype and Pht1 null mice. In this regard, there appeared to be no consistent pattern of change in either a specific amino acid transporter or brain region with respect to the up-/down-regulation between genotypes. Using hypothalamus as an example, since the in vitro inhibition studies were performed in this brain region along with in vivo studies, the only amino acid transporter that showed a statistically significant difference was Ntt4, with gene expression being reduced by only 12% (Fig. 2) . However, in Pht1 null mice, the in vivo uptake of L-His was reduced 2-fold relative to the values observed in wildtype animals (Fig. 6) . Moreover, similar reductions in the in vivo L-His uptake were observed in other brain regions even though Ntt4 gene expression increased 2-fold in cortex, had no change in cerebellum, and was reduced by only 20% in hippocampus. These findings make it unlikely that changes in the gene expression of amino acid transporters can explain the differences in transport activity of L-His during Pht1 ablation. Still, it would be important to measure, in future studies, if protein expression had also changed.
PHT1 made a significant contribution towards L-His disposition in brain slices. With PHT1 ablation, L-His uptake was reduced by 50% in vitro during 3-min brain slice incubations, and by 28-48% in vivo in brain regions after intravenous dosing. The rat PHT1 isoform is a high affinity transporter, as judged by a K m = 17 lM for LHis uptake in oocytes expressing PHT1 protein [2] . As shown in Fig. 5 , the transport of L-His by PHT1 could be inhibited, as expected, by dipeptides (e.g., carnosine and glycylsarcosine) and excess L-His. However, an interesting finding was that some amino acids (not including L-leucine) and a system L-amino acid transport inhibitor, BCH, substantially reduced the uptake of L-His via PHT1. This phenomenon has not been reported previously. Therefore, the interaction between amino acids with positive (L-His, L-lysine) or uncharged polar (L-asparagine, L-glutamine) side chains and PHT1 needs further investigation to test whether other amino acids, in addition to L-His, are substrates for PHT1.
An effect of PHT1 ablation on the brain disposition of L-His was also found in vivo with a 28-48% reduction in uptake into brain regions after intravenous dosing (Fig. 7) . These results suggest a role of PHT1 at the blood-brain barrier. Carl et al. [44] reported the protein expression of PHT1 in hCMEC/D3 cells, an immortalized human brain endothelial cell line commonly used for in vitro blood-brain barrier studies. Those cells showed some evidence of polarized L-His and carnosine (a dipeptide) transport. The role of PHT1 in di/tripeptide, peptidomimetic and amino acid transport at the blood-brain barrier merits further investigation.
In this study, no obvious phenotype was observed when comparing the body weight, fertility, serum clinical chemistry and routine behavior of wildtype and Pht1 null mice. Indeed, this observation is not unusual during transporter ablation and, often times, requires that the animals be challenged by a certain stress (e.g., drug, chemical or disease state). This scenario was clearly demonstrated by the death of Mdr1(À/À) knockout mice during ivermectin exposure [45] and by the phototoxic ear lesions observed in Bcrp1(À/À) knockout mice when fed a diet containing alfalfa [46] . Increased neurotoxicity was also observed in Pept2 (À/À) knockout mice given chronic administration of the heme precursor 5-aminolevulinic acid [47] as well as increased analgesia in Pept2(À/À) knockout mice given the endogenous neuropeptide L-kyotorphin [48] . While this study represents an analysis of LHis disposition in the brain of wildtype and Pht1 null mice, as evaluated by in vitro brain slices and in vivo biodistribution studies, these results allow us to explore subsequently if these kinetic differences will translate into pharmacological and/or pathological differences. Still, in their initial study using wildtype and Pht1 null mice, Sasawatari et al. [27] reported that PHT1 promoted a dextran sodium sulfate-induced colitis through its interaction with Tolllike receptor 9 and NOD1-dependent innate immune responses.
Taken as a whole, it appears that PHT1 accounted for 50% of the total uptake of L-His in brain slices and L-amino acid transporters for 30% of the uptake. In addition, PHT1 ablation significantly affected the in vivo blood to brain distribution of L-His. These findings are the first of their kind and suggest that PHT1 plays an important role in histidine transport and perhaps drug delivery to neuronal and non-neuronal cell types.
Note
The authors declare no competing financial interest.
